A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.

@article{Friedrich2013ARO,
  title={A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.},
  author={Christian Friedrich and Katrin Metzmann and P. Rose and Michaela Mattheus and Sabine Pinnetti and Hans J Woerle},
  journal={Clinical therapeutics},
  year={2013},
  volume={35 1},
  pages={A33-42}
}
BACKGROUND Empagliflozin is an oral, potent, and selective inhibitor of sodium glucose cotransporter 2, inhibition of which reduces renal glucose reabsorption and results in increased urinary glucose excretion. Linagliptin is an oral inhibitor of dipeptidyl peptidase-4 approved for the treatment of type 2 diabetes in the United States, Europe, Japan, and Canada. Due to their complementary modes of action, there is a good rationale to combine empagliflozin with linagliptin to improve glycemic… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Efficacy and safety of BI 10773 , a new sodium glucose cotransporter ( SGLT - 2 ) inhibitor , in type 2 diabetes inadequately controlled on metformin

  • J Rosenstock, A Jelaska, L Seman
  • Diabetes
  • 2011

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea : a 24 - week randomized study

  • S Macha, A Port, S Dieterich
  • Diabet Med
  • 2011

BI 10773 , a sodium - glucose cotransporter inhibitor ( SGLT - 2 ) , is safe and efficacious following 4 - week treatment in patients with type 2

  • T Heise, E Seewaldt-Becker, S Macha
  • DIABETES
  • 2010

Similar Papers

Loading similar papers…